BFM
BPMC

Boothbay Fund Management’s Blueprint Medicines BPMC Stock Holding History

Boothbay Fund Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-123
Closed -$1.2M – 1857
2021
Q1 		$1.2M Hold
123
– – 0.04% 510
2020
Q4 		$1.38M Buy
+123
New +$13K 0.05% 379
2020
Q3 		– Sell
-505
Closed -$3.94M – 1053
2020
Q2 		$3.94M Buy
505
+414
+455% +$28K 0.27% 82
2020
Q1 		$532K Buy
+91
New +$5.86K 0.04% 447

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boothbay Fund Management's BPMC Position: Q2 2025 in Review

Boothbay Fund Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 36,454 shares — an estimated $3.23M sold.

Boothbay Fund Management first reported a position in BPMC in Q3 2018 and held it in 11 quarters. The position peaked at $4.32M in Q4 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Boothbay Fund Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 36,454 Blueprint Medicines shares in Q2 2025, an estimated $3.23M.
  • Boothbay Fund Management first reported a position in Blueprint Medicines in Q3 2018 and held it in 11 quarters.
  • Boothbay Fund Management's Blueprint Medicines position peaked at $4.32M in Q4 2024.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.